Literature DB >> 23423250

Qualitative validation of the FACIT-fatigue scale in systemic lupus erythematosus.

M Kosinski1, K Gajria, A W Fernandes, D Cella.   

Abstract

OBJECTIVE: Fatigue in systemic lupus erythematosus (SLE) is burdensome and must be assessed using validated scales. Although the psychometric properties of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale in SLE have been evaluated previously, its content validity in this disease remains to be evaluated. The study objective was, therefore, to evaluate content validity of the FACIT-Fatigue in SLE.
METHODS: Three SLE focus groups (n=21) in the United States were conducted using semi-structured interviews. Participant comments were categorized by response type, and relative response strength was qualitatively assessed.
RESULTS: Participants were mostly female (90%; n=19), white (57%; n=12) with a mean age of 43.7 years (range=28-70). Most scale items were considered relevant with the exception of four items for which participant interpretations varied. Consistent with the scale's measurement model, "listless" on item 3 ("I feel listless ('washed out')") was interpreted as physical or mental impairment. Participant responses to item 8 ("I am able to do my usual activities") sometimes included influence of other health conditions, which is acceptable because it is difficult to separate disease-specific and general fatigue. Some participants found item 7 ("I have energy") irrelevant and most could not relate to item 10 ("I am too tired to eat"). However, both items were intended to capture the extreme ends of fatigue (item 7, ceiling; item 10, floor).
CONCLUSIONS: From a content perspective, items of the FACIT-Fatigue scale were relevant for measuring fatigue in SLE.

Entities:  

Mesh:

Year:  2013        PMID: 23423250     DOI: 10.1177/0961203313476360

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  17 in total

1.  Anti-NR2 antibodies, blood-brain barrier, and cognitive dysfunction.

Authors:  Gaurav Gulati; Philip H Iffland; Damir Janigro; Bin Zhang; Michael E Luggen
Journal:  Clin Rheumatol       Date:  2016-06-29       Impact factor: 2.980

2.  Self-reported disease severity in women with systemic lupus erythematosus.

Authors:  A Dima; S Caraiola; C Delcea; R A Ionescu; C Jurcut; C Badea
Journal:  Rheumatol Int       Date:  2018-11-10       Impact factor: 2.631

3.  Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805.

Authors:  Ryne Estabrook; David Cella; Fengmin Zhao; Judith Manola; Robert S DiPaola; Lynne I Wagner; Naomi B Haas
Journal:  Qual Life Res       Date:  2018-03-05       Impact factor: 4.147

4.  Health-related quality of life, fatigue and health utilities in lupus nephritis: A systematic literature review.

Authors:  Saifuddin Kharawala; Gavneet Kaur; Hemlata Shukla; David Alexander Scott; Neil Hawkins; Wen-Hung Chen; Kerry Gairy
Journal:  Lupus       Date:  2022-05-23       Impact factor: 2.858

Review 5.  Lupus nephritis.

Authors:  Hans-Joachim Anders; Ramesh Saxena; Ming-Hui Zhao; Ioannis Parodis; Jane E Salmon; Chandra Mohan
Journal:  Nat Rev Dis Primers       Date:  2020-01-23       Impact factor: 52.329

6.  Qualitative and quantitative validation of the FACIT-fatigue scale in iron deficiency anemia.

Authors:  Sarah Acaster; Rene Dickerhoof; Kendra DeBusk; Kristine Bernard; William Strauss; Lee F Allen
Journal:  Health Qual Life Outcomes       Date:  2015-05-17       Impact factor: 3.186

Review 7.  Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance.

Authors:  Laura Holloway; Louise Humphrey; Louise Heron; Claire Pilling; Helen Kitchen; Lise Højbjerre; Martin Strandberg-Larsen; Brian Bekker Hansen
Journal:  Health Qual Life Outcomes       Date:  2014-07-22       Impact factor: 3.186

8.  Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial.

Authors:  J J Fiechtner; T Montroy
Journal:  Lupus       Date:  2014-05-02       Impact factor: 2.911

9.  Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review.

Authors:  Vibeke Strand; Lee S Simon; Alexa Simon Meara; Zahi Touma
Journal:  Lupus Sci Med       Date:  2020-06

10.  Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.

Authors:  Edward M Vital; Joan T Merrill; Eric F Morand; Richard A Furie; Ian N Bruce; Yoshiya Tanaka; Susan Manzi; Kenneth C Kalunian; Rubana N Kalyani; Katie Streicher; Gabriel Abreu; Raj Tummala
Journal:  Ann Rheum Dis       Date:  2022-03-25       Impact factor: 27.973

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.